Core Insights - Palvella Therapeutics announced positive topline results from the Phase 3 SELVA study of QTORIN™ rapamycin for treating microcystic lymphatic malformations, meeting its primary endpoint with a statistically significant improvement [2][3] - The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, with potential approval in the first half of 2027 [3][10] Study Results - The primary endpoint, the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA), showed a mean improvement of +2.13 points (p<0.001) [5][6] - 95% of participants aged ≥ 6 who completed the efficacy evaluation improved on the mLM-IGA at Week 24, with 86% rated as "Much Improved" or "Very Much Improved" [6][9] - All four secondary efficacy endpoints also achieved statistical significance (all p<0.001) [2][5] Safety and Tolerability - QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events reported and systemic rapamycin levels below 2 ng/mL at all timepoints [6][8] - Among the 50 participants, 70% experienced treatment-emergent adverse events, but all were rated mild or moderate [8][9] Future Plans - Palvella aims to present detailed results from the SELVA study at upcoming medical meetings and is advancing QTORIN™ rapamycin for other rare skin diseases [11] - The company has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for QTORIN™ rapamycin [10]

Core Insights - CECO Environmental and Thermon Group have announced a definitive agreement to combine in a transaction valued at approximately $2.2 billion, which will enhance CECO's capabilities in industrial process heating and thermal management [1][2][4] Company Overview - CECO Environmental is a diversified industrial company focused on environmentally friendly solutions, while Thermon is a leader in industrial process heating and temperature management [13][14] - The combined company will operate under the CECO Environmental name and will be led by CEO Todd Gleason, with two members from Thermon's board joining CECO's board [1][8] Strategic Benefits - The merger is expected to create a world-class industrial solutions platform, enhancing CECO's leadership in industrial environmental and thermal solutions [2][4] - The combination will provide a comprehensive platform of industrial solutions, addressing critical areas such as thermal and acoustic management, emissions control, and industrial air quality [4][5] Financial Aspects - The transaction will be funded through a mix of cash and stock, with Thermon shareholders having multiple options for consideration, including a mixed option valued at approximately $63.13 per share, representing a 26.8% premium over Thermon's closing stock price [6][7] - The combined entity is projected to generate approximately $40 million in annual cost synergies within 36 months, enhancing its financial profile and resilience [11] Market Position and Growth - The merger positions the combined company to capitalize on durable secular trends such as energy transition, decarbonization, and tightening environmental regulations, which are expected to drive long-term growth [2][11] - The integration of both companies is anticipated to accelerate growth through expanded customer relationships and global reach [2][4]

Company Announcement Copenhagen, 24 February 2026 No. 12/2026 Acquisition of ISS A/S shares by Members of the Board of DirectorsISS A/S, a leading workplace experience and facility management company, has received notification pursuant to article 19 of the Market Abuse Regulation of transactions in ISS A/S’ shares made by persons discharging managerial responsibilities in ISS A/S and/or their closely associated persons. Member of the Board of Directors Henriette Hallberg Thygesen has purchased 3,000 shares ...

Wan Chai, HK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Looper Robotics is gearing up for the global launch of Insight9, the world’s first Autonomous Spatial AI Camera engineered by the spatial intelligence powerhouse DeepMirror. In a strategic move to democratize high-end robot perception, the company will soon publish the global premiere of Insight 9 on Kickstarter, the world's premier platform for cutting-edge tech innovation. Looper Robotics is pivoting the industry away from "stunt robotics" toward the essent ...

Core Insights - Quavo, Inc. has partnered with Apple Federal Credit Union to enhance dispute management operations using its QFD® platform, aiming to improve efficiency and member experience [1][3] Company Overview - Quavo is a technology partner for financial institutions, focusing on automating the dispute lifecycle from intake to resolution, thereby enhancing customer trust and loyalty [4] - Apple Federal Credit Union, established in 1956, serves nearly 270,000 members with $5.4 billion in assets, emphasizing community involvement and financial literacy [5] Technology and Benefits - The QFD® platform is designed specifically for financial institutions, automating the disputes process and trained on over 20 million real-world cases, which helps reduce manual workloads and speeds up resolution times [2] - Key benefits for Apple FCU members include a streamlined self-service portal, real-time claim visibility, and faster dispute outcomes, which collectively enhance the overall member experience [6]

STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, including two corresponding posters. The ...

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- BIGG Digital Assets Inc. (“BIGG” or the “Company”) (TSXV: BIGG; OTCQB: BBKCF; WKN: A2PS9W), a leading innovator and owner of Netcoins, Blockchain Intelligence Group, and TerraZero, is pleased to announce the appointment of Fraser Matthews as Chief Executive Officer (CEO), effective immediately. Mr. Matthews succeeds Dan Reitzik, who has been serving as Interim Chief Executive Officer. As Chief Executive Officer, Mr. Matthews will lead BIGG’s nex ...

Core Insights - Financial stress in Canada increased in Q4 2025, but at a slower rate compared to previous years, with older consumers showing resilience while younger consumers and those in Ontario and Western provinces exhibited financial weakening [1] Consumer Debt Trends - Total consumer debt reached $2.65 trillion in Q4 2025, marking a 3.13% year-over-year increase, driven by a $50.26 billion rise in mortgage balances and a 4.50% increase in non-mortgage debt [2] - Delinquency rates for non-mortgage debt rose, with 90+ day delinquency increasing from 1.64% to 1.73%, a year-over-year increase of 5.43% [2] Age Group Analysis - Consumers aged 26 to 35 experienced the highest credit stress, with a delinquency rate of 2.55% and an 8.39% year-over-year decline in credit health [3] Regional Divergence - A "two Canadas" scenario emerged, with Ontario experiencing the fastest growth in non-mortgage delinquency at 10.31% compared to Q4 2024, while regions with better housing affordability like Prince Edward Island and Nova Scotia saw decreases in delinquency rates [4] Credit Card Spending - Credit card spending during the 2025 holiday season decreased by 0.7% year-over-year to $2,297, with younger consumers (aged 26-35) reducing their holiday spending by 2.0% [5] - Despite reduced spending, credit card balances reached a historic $131 billion, an increase of 4.04% [5] Borrowing Power and Credit Access - Lenders tightened access to credit for riskier borrowers, with non-mortgage debt for subprime consumers remaining stagnant, while super prime consumers saw a 6.1% increase in average non-mortgage debt to $20,818 [6] Mortgage Market Dynamics - Total mortgage debt reached $1.95 trillion in Q4 2025, a 2.6% year-over-year increase, with mortgage renewals dominating the market [7] - Average new loan amounts increased by 4.1% to $363,778, with first-time homebuyers facing an average new loan size of $441,301, up 5% [8] Interest Rate Impact - The Bank of Canada's 2.25% policy rate provided some relief, but housing affordability remained strained, particularly in high-priced regions like Ontario and British Columbia [8] - Rising missed payments on higher-value mortgages in Ontario indicated that post-renewal payment levels were too high for some consumers [9]

Core Points - The Annual General Meeting of Festi hf. is scheduled for March 5, 2026, at 10:00 a.m. at the company's headquarters in Kópavogur [1] - The agenda and proposals published on February 10, 2026, remain unchanged, and no additional proposals were received from shareholders for the Nomination Committee [1] - The deadline for submitting candidacies for the Board of Directors has passed, and the Board will be elected unopposed at the Annual General Meeting [2] Board of Directors Candidates - The following individuals have submitted candidacies for the Board of Directors: Edda Blumenstein, Guðjón Auðunsson, Guðjón Reynisson, Hjörleifur Pálsson, and Sigurlína Ingvarsdóttir [4] - The Board of Directors will consist of five members elected for a one-year term at the Annual General Meeting [2] Meeting Information - Meeting materials and additional information regarding the Annual General Meeting can be found on the company's website [3] - For further inquiries, contact Ásta S. Fjeldsted, CEO of Festi hf. [3]

Core Viewpoint - Amoéba is in the final phase of obtaining marketing authorization for its biocontrol product AXPERA in France, with the assessment process led by ANSES, the French Agency for Food, Environmental and Occupational Health & Safety [1][9]. Group 1: Marketing Authorization Process - The marketing authorization application for AXPERA was submitted in March 2025, and France is acting as the rapporteur Member State for the assessment [2]. - The final stage of the assessment includes a comment phase on the draft Registration Report, which is open until March 6, 2026, after which the official marketing authorization will be published [3]. - Amoéba believes there are no obstacles to the marketing authorization, as all requested uses have been deemed acceptable and the product's safety profile confirmed [4]. Group 2: Derogatory Authorizations - Agricultural sectors in France and Italy are seeking exceptional marketing authorizations for AXPERA to address phytosanitary emergencies, similar to the authorization granted in 2025 for use against downy mildew in vineyards [5]. - A new application for exceptional authorization for large-scale trials in the Netherlands has been submitted, allowing AXPERA to be used on multiple crops [6]. - If granted, these derogatory authorizations would enable AXPERA to be marketed for specific uses regardless of the final timetable for standard marketing authorization [7]. Group 3: Company Overview - Founded in 2010, Amoéba specializes in microbiological risk treatment using patented amoebae technology for plant protection and cosmetics [8]. - The company is the only one authorized to use Willaertia amoeba industrially for biocontrol and cosmetic applications, with a focus on the global biocontrol market [10]. - The active substance of AXPERA has been approved in the United States since 2022, and product registration is expected in France in 2026 [11].